Workshop: Methamphetamine-Associated Psychosis (MAP): Clinical Challenges and Approaches to Management-Methamphetamine-Associated Psychosis (MAP): Clinical Challenges and Approaches to Management

Video Transcription

Video Summary

The video workshop discusses methamphetamine psychosis and treatment approaches. The speakers highlight the increase in methamphetamine use and overdose deaths, as well as the relationship between methamphetamine and psychosis. They discuss the differences between meth psychosis and schizophrenia and the importance of a comprehensive approach to treatment. The use of antipsychotic medications, such as olanzapine and risperidone, is explored, along with considerations for patient preference, side effects, and treatment history. The workshop emphasizes the importance of a therapeutic relationship and delivering stigma-free care. <br /><br />In a case presentation, the video discusses a 32-year-old man with a history of methamphetamine use disorder and schizoaffective disorder who is currently stable without psychotic symptoms. The group discusses the challenges in diagnosing and managing methamphetamine-induced psychosis and the use of antipsychotic medications. They explore the potential benefits and drawbacks of tapering off antipsychotics based on factors such as stability and patient preference. They consider the use of long-acting injectable antipsychotics and the importance of social factors in treatment planning. The meaning and function of methamphetamine use in the patient's life are recognized as important considerations. The role of other medications, such as naltrexone and bupropion, in managing cravings and comorbid opioid use disorder is also discussed. Ultimately, the video emphasizes the need for individualized treatment approaches that take into account the patient's circumstances and preferences.

Keywords

methamphetamine psychosis

treatment approaches

methamphetamine use

overdose deaths

relationship between methamphetamine and psychosis

meth psychosis

schizophrenia

antipsychotic medications

patient preference

stigma-free care

long-acting injectable antipsychotics

comorbid opioid use disorder

individualized treatment approaches

	The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.		400 Massasoit Avenue Suite 108 East Providence, RI 02914 cmecpd@aaap.org Privacy	About Advocacy Membership Fellowship Education and Resources Training Events